Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Articles online first > Minerva Endocrinologica 2016 Dec 20

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

MINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

Minerva Endocrinologica 2016 Dec 20

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion

Manuel GONZÁLEZ-ORTIZ, Miriam MÉNDEZ-DEL VILLAR, Esperanza MARTÍNEZ-ABUNDIS, Alejandra M. RAMÍREZ-RODRÍGUEZ

Institute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Mexico


PDF  


AIM: To evaluate the effect of dapagliflozin on metabolic syndrome (MetS), insulin sensitivity and insulin secretion.
METHODS: A randomized, double blind, placebo-controlled clinical trial was carried out in 24 patients with MetS. Glucose and insulin levels were measured every 30 min for 2-h after a 75-g dextrose load. Metabolic profile was also evaluated before and after the pharmacological intervention. Twelve patients received dapagliflozin (10 mg) before breakfast for 90 days. The remaining 12 patients received placebo. Area under the curve (AUC) of glucose and insulin, total insulin secretion, first-phase of insulin secretion and insulin sensitivity were calculated. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Ethics Committee approved the study protocol.
RESULTS: After dapagliflozin, there were significant decreases in body weight (82.8 ± 12.9 vs. 81.2 ± 12.9 kg, p <0.001), BMI (33.4 ± 3.6 vs. 32.7 ± 3.7 kg/m2, p <0.001), waist circumference (102 ± 10 vs. 98 ± 9 cm, p<0.001), total cholesterol (5.4 ± 0.7 vs. 5.2 ± 0.7 mmol/L, p = 0.049), triglycerides (2.7 ± 1.4 vs. 1.7 ± 0.8 mmol/L, p = 0.003), AUC of insulin (103,914 ± 55,170 vs. 45,018 ± 22,146 pmol/L, p <0.001) and total insulin secretion (0.84 ± 0.64 vs. 0.35 ± 0.11, p <0.001). Seven patients (58.3%) in the dapagliflozin group showed remission of MetS (p = 0.027).
CONCLUSIONS: Dapagliflozin decreased body weight, BMI, waist circumference, total cholesterol, triglycerides, AUC of insulin and total insulin secretion, with a remission of MetS in 58.3%.


KEY WORDS: Dapagliflozin - Metabolic syndrome - Insulin sensitivity - Insulin secretion

inizio pagina

Publication History

Per citare questo articolo

González-Ortiz M, Méndez-Del Villar M, Martínez-Abundis E, Ramírez-Rodríguez AM. Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol 2016 Dec 20. 

Corresponding author e-mail

uiec@prodigy.net.mx